• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于药物浓度阈值的不依从性检测的受试者工作特征框架-在精神分裂症患者模拟利培酮数据中的应用。

A Receiver Operating Characteristic Framework for Non-adherence Detection Using Drug Concentration Thresholds-Application to Simulated Risperidone Data in Schizophrenic Patients.

机构信息

Janssen Research & Development, Clinical Pharmacology & Pharmacometrics, Beerse, Belgium.

Janssen Research & Development, Quantitative Sciences Consulting, Beerse, Belgium.

出版信息

AAPS J. 2019 Mar 14;21(3):40. doi: 10.1208/s12248-019-0299-9.

DOI:10.1208/s12248-019-0299-9
PMID:30874997
Abstract

Non-adherence to antipsychotic medication is a primary factor in disease relapse in schizophrenic patients. We sought to evaluate if plasma concentrations of the antipsychotic risperidone can be used as a predictor of treatment adherence and to identify the optimal plasma concentration threshold to reliably distinguish between adherent and non-adherent patients. A population pharmacokinetic model was used to simulate plasma risperidone steady-state trough concentrations in 1000 virtual patients, where 60% of the patients were 100% adherent to their medication, while 40% of the patients were non-adherent to their medication. The probability of adherence was assessed by receiver operating characteristic (ROC) analysis on C. The area under the ROC curve (AUC) was used to identify the optimal C threshold. Single vs multiple C at steady state was also evaluated. After a single risperidone C measurement, the AUC (95% CI) was estimated to be 0.71 (0.69-0.72) and the optimal C threshold accounting for the lowest number of adherent and non-adherent misclassifications was estimated to be 11.9 ng/mL. After multiple C measurements, the AUC (95% CI) increased up to 0.85 (0.84-0.87) for three C measurements. The optimal probability threshold to reliably discriminate between adherent and non-adherent patients was estimated to be 0.51. Using this model which is reflective of typical adherence to antipsychotic medication, we found that three consecutive steady-state C measurements are needed for an accurate and precise diagnostic test to discriminate between patients who are adherent or non-adherent to treatment.

摘要

抗精神病药物治疗不依从是精神分裂症患者疾病复发的主要因素。我们旨在评估抗精神病药利培酮的血浆浓度是否可用作治疗依从性的预测指标,并确定可靠地区分依从性和非依从性患者的最佳血浆浓度阈值。使用群体药代动力学模型模拟了 1000 名虚拟患者的利培酮稳态谷浓度,其中 60%的患者对其药物治疗 100%依从,而 40%的患者不依从其药物治疗。通过 C 值的接收者操作特征 (ROC) 分析评估依从性的概率。ROC 曲线下面积 (AUC) 用于确定最佳 C 值阈值。还评估了稳态下的单次与多次 C 值。单次利培酮 C 值测量后,AUC(95%CI)估计为 0.71(0.69-0.72),且估计能使最少数量的依从性和非依从性误分类的最低 C 值阈值为 11.9ng/mL。多次 C 值测量后,AUC(95%CI)增加至 0.85(0.84-0.87),进行三次 C 值测量。估计可靠地区分依从性和非依从性患者的最佳概率阈值为 0.51。使用反映典型抗精神病药物治疗依从性的此模型,我们发现需要进行三次连续的稳态 C 值测量,以进行准确且精密的诊断试验来区分依从性和非依从性患者。

相似文献

1
A Receiver Operating Characteristic Framework for Non-adherence Detection Using Drug Concentration Thresholds-Application to Simulated Risperidone Data in Schizophrenic Patients.基于药物浓度阈值的不依从性检测的受试者工作特征框架-在精神分裂症患者模拟利培酮数据中的应用。
AAPS J. 2019 Mar 14;21(3):40. doi: 10.1208/s12248-019-0299-9.
2
Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients.利培酮代谢率作为精神分裂症患者个体CYP2D6基因型的生物标志物。
Eur J Clin Pharmacol. 2014 Jun;70(6):695-9. doi: 10.1007/s00228-014-1664-3. Epub 2014 Mar 20.
3
Population pharmacokinetic-pharmacodynamic (PopPK/PD) modeling of risperidone and its active metabolite in Chinese schizophrenia patients.利培酮及其活性代谢产物在中国精神分裂症患者中的群体药代动力学-药效学(PopPK/PD)模型
Int J Clin Pharmacol Ther. 2016 May;54(5):378-89. doi: 10.5414/CP202498.
4
Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.抗精神病药血药浓度与干预有效性临床试验(CATIE)研究期间治疗失败的关系。
Schizophr Res. 2018 Nov;201:324-328. doi: 10.1016/j.schres.2018.05.028. Epub 2018 May 24.
5
Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.CYP2D6基因多态性对日本精神分裂症患者血浆中利培酮及9-羟基利培酮对映体浓度的影响。
J Clin Pharmacol. 2003 Feb;43(2):122-7. doi: 10.1177/0091270002239819.
6
Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders.利培酮在患有精神或神经发育障碍儿童中的血浆药代动力学特征及其与唾液浓度的关系。
Clin Ther. 2007 Jul;29(7):1476-86. doi: 10.1016/j.clinthera.2007.07.026.
7
Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone.
J Clin Pharmacol. 2002 Oct;42(10):1083-8. doi: 10.1177/009127002401382678.
8
Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3(1/2) years duration.预测老年精神分裂症患者(利培酮或奥氮平)对非典型抗精神病药物的依从性:一项为期 3(1/2)年的开放性研究。
Int J Geriatr Psychiatry. 2010 Apr;25(4):411-8. doi: 10.1002/gps.2354.
9
Increase in risperidone plasma level with lamotrigine.联用拉莫三嗪时利培酮血浆水平升高。
Am J Psychiatry. 2005 Apr;162(4):811-2. doi: 10.1176/appi.ajp.162.4.811-a.
10
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.
J Clin Psychopharmacol. 2002 Aug;22(4):419-23. doi: 10.1097/00004714-200208000-00014.

引用本文的文献

1
Conditional distribution modeling as an alternative method for covariates simulation: Comparison with joint multivariate normal and bootstrap techniques.条件分布建模作为协变量模拟的一种替代方法:与联合多元正态和自举技术的比较。
CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):330-339. doi: 10.1002/psp4.12613.

本文引用的文献

1
Receiver Operating Characteristic Analysis and Clinical Trial Simulation to Inform Dose Titration Decisions.受试者工作特征分析和临床试验模拟用于辅助剂量滴定决策。
CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):771-779. doi: 10.1002/psp4.12354. Epub 2018 Oct 15.
2
Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.抗精神病药血药浓度与干预有效性临床试验(CATIE)研究期间治疗失败的关系。
Schizophr Res. 2018 Nov;201:324-328. doi: 10.1016/j.schres.2018.05.028. Epub 2018 May 24.
3
Determination of Plasma Concentration Reference Ranges for Risperidone and Paliperidone.
测定利培酮和帕利哌酮的血浆浓度参考范围。
CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):589-595. doi: 10.1002/psp4.12217. Epub 2017 Aug 29.
4
Relationship Between Adherence Rate Threshold and Drug 'Forgiveness'.药物“宽容度”与服药依从性阈值的关系
Clin Pharmacokinet. 2017 Dec;56(12):1435-1440. doi: 10.1007/s40262-017-0552-2.
5
The Role of Antipsychotic Plasma Levels in the Treatment of Schizophrenia.抗精神病药物血浆水平在精神分裂症治疗中的作用
Am J Psychiatry. 2017 May 1;174(5):421-426. doi: 10.1176/appi.ajp.2016.16040402.
6
Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode.精神分裂症的药理学指南:首次发作建议的系统评价与比较
BMJ Open. 2017 Jan 6;7(1):e013881. doi: 10.1136/bmjopen-2016-013881.
7
Bayesian population modeling of drug dosing adherence.药物剂量依从性的贝叶斯群体建模
J Pharmacokinet Pharmacodyn. 2015 Oct;42(5):515-25. doi: 10.1007/s10928-015-9439-8. Epub 2015 Aug 29.
8
Medication adherence in schizophrenia.精神分裂症患者的药物依从性。
World J Psychiatry. 2012 Oct 22;2(5):74-82. doi: 10.5498/wjp.v2.i5.74.
9
Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review.精神分裂症患者的药物依从性:影响依从性的因素及不依从的后果,系统文献回顾。
Ther Adv Psychopharmacol. 2013 Aug;3(4):200-18. doi: 10.1177/2045125312474019.
10
The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data.利用ROC分析从动物数据对人体口服生物利用度进行定性预测。
Pharm Res. 2014 Mar;31(3):720-30. doi: 10.1007/s11095-013-1193-2. Epub 2013 Sep 27.